D. G. McCarver

发表

Developmental Expression of Human Hepatic CYP2C9 and CYP2C19

A. Rettie, S. B. Koukouritaki, J. Manro, 2004, Journal of Pharmacology and Experimental Therapeutics.

Prevention of Medication Errors * in the Pediatric Inpatient Setting

Marleta Reynolds, Daniel A. Notterman, D. Notterman, 1998, Pediatrics.

Cytochrome P4502D6 (CYP2D6) Gene Locus Heterogeneity: Characterization of Gene Duplication Events

I Zineh, J. Johnson, I. Zineh, 2007, Clinical pharmacology and therapeutics.

Genetic Variability at the Human FMO1 Locus: Significance of a Basal Promoter Yin Yang 1 Element Polymorphism (FMO1*6)

S. B. Koukouritaki, D. G. McCarver, R. Hines, 2003, Journal of Pharmacology and Experimental Therapeutics.

Genetic polymorphisms in human drug metabolic enzymes.

J. Goldstein, D. Bell, D. Eaton, 1997, Fundamental and applied toxicology : official journal of the Society of Toxicology.

Genetic Polymorphisms in Human Drug Metabolic Enzymes 1

J. Goldstein, D. Bell, D. Eaton, 2005 .

The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.

D. G. McCarver, R. Hines, And D Gail Mccarver, 2002, The Journal of pharmacology and experimental therapeutics.

Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis.

R. Kim, A. Rettie, D. G. McCarver, 2003, Toxicology and applied pharmacology.

The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis.

D. G. McCarver, D. Brousseau, J. Panepinto, 2007, The Journal of pediatrics.

Trichloroethylene decreases heat shock protein 90 interactions with endothelial nitric oxide synthase: implications for endothelial cell proliferation.

K. Pritchard, D. G. McCarver, R. Hines, 2003, Toxicological sciences : an official journal of the Society of Toxicology.

Human Hepatic CYP2E1 Expression during Development

S. B. Koukouritaki, D. G. McCarver, R. Hines, 2003, Journal of Pharmacology and Experimental Therapeutics.

A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake.

D. G. McCarver, R. Hines, R. Byun, 1998, Toxicology and applied pharmacology.

Proximity of residence to trichloroethylene-emitting sites and increased risk of offspring congenital heart defects among older women.

D. G. McCarver, Marsha E Malloy, D. McCarver, 2004, Birth defects research. Part A, Clinical and molecular teratology.

Developmental Expression of Human Hepatic CYP 2 C 9 and CYP 2 C 19

A. Rettie, S. B. Koukouritaki, J. Manro, 2003 .

Determination of Human Hepatic CYP2C8 and CYP1A2 Age-Dependent Expression to Support Human Health Risk Assessment for Early Ages

B. Lake, H. Clewell, Xueying Sun, 2017, Drug Metabolism and Disposition.

The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms.

D. G. McCarver, R. Hines, D. McCarver, 2002, The Journal of pharmacology and experimental therapeutics.

Prevention and management of pain and stress in the neonate

D. Notterman, L. Wright, A. Fanaroff, 2000 .

"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs.

D. Notterman, S. Szefler, M. Rieder, 1997, Pediatrics.

Role of Chromatin Structural Changes in Regulating Human CYP3A Ontogeny

S. Strom, K. Dorko, P. Simpson, 2016, Drug Metabolism and Disposition.

Pharmacogenomics and the future of drug therapy.

D. G. McCarver, R. Hines, D. McCarver, 2006, Pediatric clinics of North America.

Alcohol dehydrogenase-2*3 allele protects against alcohol-related birth defects among African Americans.

Ting-kai Li, R. Sokol, D. G. McCarver, 1997, The Journal of pharmacology and experimental therapeutics.

Age-Dependent Human Hepatic Carboxylesterase 1 (CES1) and Carboxylesterase 2 (CES2) Postnatal Ontogeny

P. Simpson, D. G. McCarver, R. Hines, 2016, Drug Metabolism and Disposition.

Applicability of the principles of developmental pharmacology to the study of environmental toxicants.

D. G. McCarver, D. McCarver, 2004, Pediatrics.

Discovery of Novel Flavin-Containing Monooxygenase 3 (FMO3) Single Nucleotide Polymorphisms and Functional Analysis of Upstream Haplotype Variants

S. B. Koukouritaki, D. G. McCarver, R. Hines, 2005, Molecular Pharmacology.

Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in African-Americans.

D. Williams, J. Kang, J. Whetstine, 2000, Toxicology and applied pharmacology.

Ethnic differences in allelic frequency of two flavin-containing monooxygenase 3 (FMO3) polymorphisms: linkage and effects on in vivo and in vitro FMO activities.

D. G. McCarver, R. Hines, Chang-Shin Park, 2002, Pharmacogenetics.

Population-Based Analysis of Methadone Distribution and Metabolism Using an Age-Dependent Physiologically Based Pharmacokinetic Model

D. Beard, Feng Yang, D. G. McCarver, 2006, Journal of Pharmacokinetics and Pharmacodynamics.

ADH2 and CYP2E1 genetic polymorphisms: risk factors for alcohol-related birth defects.

D. G. McCarver, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Knowledge and misconceptions among inner-city African-American mothers regarding alcohol and drug use.

D. G. McCarver, J. Mowery, F. M. Donnelly, 1998, The American journal of drug and alcohol abuse.

Human hepatic UGT2B15 developmental expression.

D. G. McCarver, R. Hines, K. Divakaran, 2014, Toxicological sciences : an official journal of the Society of Toxicology.

Human hepatic CYP2E1 expression during development.

Ronald N Hines, S. B. Koukouritaki, D. G. McCarver, 2003, The Journal of pharmacology and experimental therapeutics.

Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene.

K Krishnan, K. Krishnan, A. Nong, 2006, Toxicology and applied pharmacology.

Identification and Functional Analysis of a Novel Human CYP2E1 Far Upstream Enhancer

D. G. McCarver, R. Hines, Kirk A. Douglas, 2007, Molecular Pharmacology.

Development of dapsone toxicity in patients with inflammatory dermatoses: Activity of acetylation and hydroxylation of dapsone as risk factors

R. Branch, D. G. McCarver, A. Adedoyin, 1999, Clinical pharmacology and therapeutics.

Alcohol dehydrogenase 2*3 affects alterations in offspring facial morphology associated with maternal ethanol intake in pregnancy.

D. G. McCarver, S. Martier, C. Cronk, 2004, Alcoholism, clinical and experimental research.

Genetic Polymorphisms in Human Drug Metabolic Enzymes

J. Goldstein, D. Bell, D. Eaton, 1997 .

Prevention and management of pain and stress in the neonate.

D. Notterman, L. Wright, A. Fanaroff, 2000, Paediatrics & child health.

Pediatric Drug Disposition and Pharmacokinetics Age-Dependent Human Hepatic Carboxylesterase 1 ( CES 1 ) and Carboxylesterase 2 ( CES 2 ) Postnatal Ontogeny

P. Simpson, D. G. McCarver, R. Hines, 2016 .

"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs.

D. Notterman, S. Szefler, M. Rieder, 1997, Pediatrics.